BLFSNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
BIOLIFE SOLUTIONS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$38.61+0.00 (0.00%)
Close on Oct 7, 2026
- Market cap
- $1.90B
- P/E (TTM)
- 33.6
- Dividend yield
- –
Share price
+$12.09 (+45.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BIOLIFE SOLUTIONS INC grew revenue 25.4% to $102.82M over the twelve months to Jun 30, 2026. Free cash flow was $10.64M, up 104.4% from a year earlier.
Revenue
$102.82M
+25.4% vs. a year earlier
Operating income
$2.98M
TTM Q2 2026
Free cash flow
$10.64M
+104.4% vs. a year earlier
EPS, diluted
$1.15
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.90B
- P/E ratio
- 33.6
- Price to sales
- 18.51
- Price to book
- 4.53
- Dividend yield
- –
- Free cash flow yield
- 0.56%
Fundamentals
- Revenue
- $102.82M
- Net income
- $57.98M
- EPS, diluted
- $1.15
- Free cash flow
- $10.64M
- Book value per share
- $8.52
- Diluted shares
- 49M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$102.82M+25.4% YoY
Gross profit
–
Operating income
$2.98M
Net income
$57.98M
EPS, diluted
$1.15
Free cash flow
–
Reported periodTrailing twelve months